SCHEMBL13724876

SCHEMBL13724876

Cc1ccccc1/C=C1/SC(=O)NC1=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTR P02766 3/20 1.00
NAT1 P18440 2/20 0.72
IGF1R P08069 2/20 0.67
GSK3B P49841 1/20 0.66
MEN1 O00255 6/20 0.63
KMT2A Q03164 6/20 0.63
AKR1B1 P15121 2/20 0.63
PIM1 P11309 4/20 0.62
PIM2 Q9P1W9 4/20 0.62
PIM3 Q86V86 2/20 0.62
HPGD P15428 3/20 0.60
TDP2 O95551 1/20 0.60
CASP7 P55210 1/20 0.60
CASP9 P55211 1/20 0.60
CASP6 P55212 1/20 0.60
CASP8 Q14790 1/20 0.60
ALDH1A1 P00352 4/20 0.55
PLA2G1B P04054 2/20 0.55
POLB P06746 2/20 0.55
HTT P42858 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15091770 1.00 TTR (1.00) TTRNAT1IGF1RGSK3BMEN1
SCHEMBL7464188 1.00 TTR (1.00) TTRNAT1IGF1RGSK3BMEN1
SCHEMBL9573270 0.84 NAT1 (1.00) TTRNAT1GSK3BMEN1KMT2A
SCHEMBL8182122 0.84 TTR (0.72) TTRNAT1IGF1RGSK3BMEN1
SCHEMBL9573277 0.84 NAT1 (1.00) TTRNAT1GSK3BMEN1KMT2A
SCHEMBL8182119 0.84 TTR (0.72) TTRNAT1IGF1RGSK3BMEN1
SCHEMBL1247451 0.81 TTR (0.68) TTRNAT1IGF1RGSK3BMEN1
SCHEMBL1247452 0.81 TTR (0.68) TTRNAT1IGF1RGSK3BMEN1
SCHEMBL6651682 0.81 TTR (0.69) TTRNAT1IGF1RGSK3BMEN1
SCHEMBL1249066 0.81 TTR (0.69) TTRIGF1RGSK3BMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090203667-A1 PENTADIENAMIDE DERIVATIVES KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-08-13 US disclosed
US-20090203667-A1 PENTADIENAMIDE DERIVATIVES KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203667-A1 PENTADIENAMIDE DERIVATIVES PRMT1, REN, NGLY1 TTR 1695/4885NAT1 18/4885IGF1R 171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.